Description

What Is the BPC-157 + TB-500 Blend?

Blend Composition: BPC-157 (5mg) + TB-500 (5mg) | Total Content: 10mg per vial | Purity: ≥99% per component (HPLC & Mass Spec verified) | Form: Lyophilized powder | Origin: US-manufactured, third-party tested

The BPC-157 + TB-500 blend is PSPeptides’ dual-peptide regenerative research formulation combining two of the most extensively studied tissue-repair compounds in published scientific literature: BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment). Often referred to in research communities as the “Wolverine Stack,” this combination pairs BPC-157’s localized cytoprotective and wound-healing properties with TB-500’s systemic cell migration and tissue remodeling activity.

This blend is designed for researchers investigating multi-pathway approaches to connective tissue repair, musculoskeletal healing, and inflammatory modulation — areas where single-peptide protocols may not engage both localized and systemic repair mechanisms simultaneously.

Blend Components and Mechanisms

BPC-157 — 5mg (Body Protection Compound-157)

Sequence: 15-amino acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) | CAS: 137525-51-0

BPC-157 is a stable gastric pentadecapeptide originally isolated from human gastric juice. It is one of the most widely studied tissue-repair peptides in published literature, with demonstrated healing activity across skin, tendon, ligament, muscle, bone, nerve, cornea, and gastrointestinal tissues in preclinical models.

Primary mechanisms studied:

• Angiogenesis promotion: BPC-157 is associated with VEGFR2 (vascular endothelial growth factor receptor 2) activation and upregulation, promoting new blood vessel formation at injury sites — a critical early step in tissue repair.
• Tendon and connective tissue repair: Published research demonstrates that BPC-157 significantly accelerates tendon fibroblast outgrowth from tendon explants, increases cell survival under oxidative stress, and promotes dose-dependent cell migration via the FAK-paxillin signaling pathway (Chang et al., 2011, J Appl Physiol).
• Wound healing: BPC-157 accelerates healing of incisional/excisional wounds, deep burns, diabetic ulcers, and alkali burns in animal models. When applied topically as a cream, it outperformed silver sulfadiazine (the standard burn treatment) and systemic corticosteroids in mouse burn models (Mikus et al., 2001).
• Nitric oxide system modulation: BPC-157 interacts with the NO system, helping to regulate vessel constriction and blood flow to injured tissue.
• Gene expression: BPC-157 rapidly increases expression of various growth factor genes in wound tissue, potentially explaining its broad-spectrum healing activity.
• Gastrointestinal cytoprotection: Originally characterized for its gastroprotective effects, BPC-157 demonstrates significant protection against NSAID-induced gastrointestinal lesions, inflammatory bowel disease models, and mucosal damage in preclinical studies (Sikiric et al., multiple publications).

TB-500 — 5mg (Thymosin Beta-4 Fragment)

Sequence: 43-amino acid peptide (fragment of Thymosin Beta-4) | CAS: 77591-33-4

TB-500 is a synthetic analog of thymosin beta-4, a naturally occurring protein found in virtually all human and animal cells. Thymosin beta-4 is one of the most abundant intracellular peptides and plays a central role in cell migration, differentiation, and tissue repair. TB-500 represents the active region of the full-length protein responsible for its primary regenerative signaling.

Primary mechanisms studied:

• Cell migration and cytoskeletal remodeling: TB-500 promotes actin polymerization and cytoskeletal reorganization, enabling cells to migrate toward sites of injury — a fundamental requirement for wound healing and tissue regeneration.
• Angiogenesis: TB-500 promotes the formation of new blood vessels in preclinical models, supporting nutrient and oxygen delivery to damaged tissue during the repair process.
• Anti-inflammatory activity: Research demonstrates that TB-500 downregulates pro-inflammatory cytokines and reduces localized inflammation in injury models, creating a more favorable environment for tissue repair.
• Collagen deposition and tissue remodeling: TB-500 enhances collagen architecture and reduces fibrotic (scar) tissue formation, supporting functional recovery rather than disorganized scarring in connective tissue models.
• Systemic distribution: Unlike many tissue-repair peptides that act locally, TB-500’s low molecular weight allows it to circulate systemically, potentially reaching injury sites throughout the body regardless of administration location.
• Hair follicle stem cell activation: Thymosin beta-4 has been shown to promote hair follicle stem cell migration and differentiation in murine models, suggesting a role in hair growth and follicular regeneration (Philp et al., 2004, Nature).

Why Combine BPC-157 and TB-500?

BPC-157 and TB-500 operate through distinct but complementary mechanisms within the tissue repair cascade. Published research and preclinical models suggest that this combination provides what researchers describe as “inside-out” healing coverage:

• Local + systemic repair: BPC-157 concentrates its activity at the site of injury through direct cytoprotective and growth-factor-mediated mechanisms, while TB-500 circulates systemically to recruit cells and promote repair across multiple tissue types simultaneously.
• Complementary angiogenesis pathways: Both peptides independently promote new blood vessel formation, but through different signaling mechanisms — BPC-157 via VEGFR2 activation and TB-500 via endothelial cell migration and actin reorganization. This dual-pathway approach may provide more robust vascular support to healing tissue.
• Anti-inflammatory synergy: BPC-157 modulates the nitric oxide system and inflammatory cytokine expression, while TB-500 independently downregulates pro-inflammatory mediators. Together, they address inflammation through multiple pathways.
• Collagen and structural repair: BPC-157 upregulates growth factor gene expression critical for collagen synthesis, while TB-500 enhances collagen architecture and reduces fibrotic scarring — potentially improving both the speed and quality of structural tissue repair.

Research Applications

The BPC-157 + TB-500 blend is commonly utilized in preclinical research models investigating:

• Tendon, ligament, and muscle repair mechanisms
• Post-surgical wound healing and recovery timelines
• Inflammatory modulation in musculoskeletal injury models
• Connective tissue regeneration and collagen remodeling
• Gastrointestinal mucosal repair and cytoprotection
• Comparative efficacy of single-peptide vs. multi-peptide tissue repair protocols

Product Specifications

Selected References

• Chang CH, et al. (2011). “BPC-157 promotes tendon fibroblast migration through the FAK-paxillin pathway.” Journal of Applied Physiology.
• Mikus D, et al. (2001). “Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice.” Burns.
• Sikiric P, et al. (2018). “Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications.” Current Neuropharmacology.
• Philp D, et al. (2004). “Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development.” Annals of the New York Academy of Sciences.
• Malinda KM, et al. (1999). “Thymosin beta 4 accelerates wound healing.” Journal of Investigative Dermatology.
• Sosne G, et al. (2010). “Thymosin beta 4: A potential novel therapy for neurotrophic keratopathy, dry eye, and ocular surface diseases.” Vitamins and Hormones.